Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds

PDF File ACRX Corporate Presentation - 2/24/15

Webcast ImageWebcast
AcelRx Pharmaceuticals, Inc. at the Cowen and Company 35th Annual Health Care Conference (Replay)
03/02/15 at 1:30 p.m. ET
AcelRx Pharmaceuticals, Inc. at the Cowen and Company 35th Annual Health Care Conference
Monday, March 2, 2015 1:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. AcelRx has announced positive results from each of the three Phase 3 clinical trials for Zalviso and has submitted an NDA to the FDA seeking its approval. AcelRx also announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from U.S. Army Medical Research and Materiel Command. The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.
ACRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$8.93
Change (%) Stock is Down 0.2 (2.19%)
Volume362,709
Data as of 03/03/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

    More >>
02/20/15AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events
REDWOOD CITY, Calif., Feb. 20, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E. Morris, chief financial officer will be presenting at RBC Capital Markets' Global Healthcare Conference and Cowen and Company's 35th Annual Healthcare Conference.  Details of the two presentations are as follows: ... 
Printer Friendly Version
02/04/15AcelRx Pharmaceuticals to Present at BIO CEO & Investor Conference
REDWOOD CITY, Calif., Feb. 4, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E Morris, Chief Financial Officer, will present a company overview and update at the 17th Annual BIO CEO & Investor Conference. Details of the presentation are as follows: BIO CEO & Investor Conference Dat... 
Printer Friendly Version
12/02/14AcelRx Pharmaceuticals Receives CE Mark Approval for Zalviso
REDWOOD CITY, Calif., Dec. 2, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device. Zalviso is a drug-device combination product utilizing the opioid agonist sufentanil formulated in a proprietary sublingual tablet formulation an... 
Printer Friendly Version

Upcoming Events

    More >>
DateTitle
03/10/15 2:00 p.m. PT
AcelRx Pharmaceuticals, Inc. at the 27th Annual Roth Conference
LocationThe Ritz-Carlton
Laguna Nigel, CA

Receive E-mail Alerts 

Sign up to receive e-mail alerts whenever AcelRx Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

AcelRX

CONTACT